Welltech Ventures
VC Fund
Tel Aviv, Israel
Welltech Ventures is a VC fund in Tel Aviv focused on Health Care and Artificial Intelligence. Welltech Ventures is Israel’s leading fund focused exclusively on investing in the health and wellness space. We seek to partner with entrepreneurs who epitomize the Startup Nation’s ethos and are building paradigm-shattering companies that are making an impact in the wellness space. As thought leaders we work with global investors focused onaccessing and investing in the Israeli tech ecosystem’s most promising entrepreneurs.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Welltech Ventures invests in
Stages Welltech Ventures invests in
Countries Welltech Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $718k–$19M
- Series A
- $6M–$20M
Investment Focus
Industry
- Health Care 6 (26%)
- Artificial Intelligence 5 (22%)
- mHealth 2 (9%)
- Wellness 2 (9%)
- Biotechnology 2 (9%)
Stage
- Seed 7 (30%)
- Series A 3 (13%)
- Venture - Series Unknown 2 (9%)
- Pre-Seed 1 (4%)
- Funding Round 1 (4%)
Country
- Israel 5 (22%)
- United States 4 (17%)
- Poland 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amir Alroy
Co-Founder, Partner
|
Co-Founder, Partner | Total investments: 5 | Find email | |
Steven Berelowitz
ADV., Partner
|
ADV., Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Marquee
|
Marquee AI is a Sports tech company that develops advanced AI platforms to analyze recruitment, scouting and performance of the player. | $4M / Seed / Jul 30, 2026 | |
Antidote Health
|
Antidote Health offers an AI-based health platform that helps people receive proper medical treatment. Antidote Health's technology streamlines patient screening and augments the doctor's decision-making process, removing the burden of administrative tasks from the doctor and improving the quality of the doctor-patient experience.Inaddition to offering all the benefits of a standard telehealth platform, Antidote Health's platform is designed to address the added layer of social health, creating a health ripple effect, spreading from doctors to patients, to families and communities which loops back to positively impact the lives of everyone involved: patients, doctors, and the communities they live in. | $7M / Series A / May 31, 2023 | |
|
Antidote Health
|
Antidote Health offers an AI-based health platform that helps people receive proper medical treatment. Antidote Health's technology streamlines patient screening and augments the doctor's decision-making process, removing the burden of administrative tasks from the doctor and improving the quality of the doctor-patient experience.Inaddition to offering all the benefits of a standard telehealth platform, Antidote Health's platform is designed to address the added layer of social health, creating a health ripple effect, spreading from doctors to patients, to families and communities which loops back to positively impact the lives of everyone involved: patients, doctors, and the communities they live in. | $7M / Series A / May 31, 2023 | |
|
Antidote Health
|
Antidote Health offers an AI-based health platform that helps people receive proper medical treatment. Antidote Health's technology streamlines patient screening and augments the doctor's decision-making process, removing the burden of administrative tasks from the doctor and improving the quality of the doctor-patient experience.Inaddition to offering all the benefits of a standard telehealth platform, Antidote Health's platform is designed to address the added layer of social health, creating a health ripple effect, spreading from doctors to patients, to families and communities which loops back to positively impact the lives of everyone involved: patients, doctors, and the communities they live in. | $7M / Series A / May 31, 2023 | |
|
Antidote Health
|
Antidote Health offers an AI-based health platform that helps people receive proper medical treatment. Antidote Health's technology streamlines patient screening and augments the doctor's decision-making process, removing the burden of administrative tasks from the doctor and improving the quality of the doctor-patient experience.Inaddition to offering all the benefits of a standard telehealth platform, Antidote Health's platform is designed to address the added layer of social health, creating a health ripple effect, spreading from doctors to patients, to families and communities which loops back to positively impact the lives of everyone involved: patients, doctors, and the communities they live in. | $7M / Series A / May 31, 2023 | |
MDI Health
|
MDI Health offers an AI-powered platform that provides unique decision support tools for personalized drug treatments. It uses its patent-pending technology, methodology, and algorithms to ensure early detection of potential Medication-Related Problems (MRPs) during the course of the drug treatment and to ensure the optimal balance between efficacyand safety of the treatment. | $20M / Series A / Feb 13, 2023 | |
Quris
|
Quris Technologies is a bio-AI clinical-prediction platform is being developed to assure the safety and efficacy of medications.The company provides a fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively while minimizing animal testing, allowing pharmacompanies to avoid the enormous risks and costs of failed clinical trials and end the reliance on ineffective animal testing.Quris Technologies was established in 2019 by Isaac Bentwich in Tel Aviv, Israel. | $9M / Seed / Dec 20, 2022 | |
|
Quris
|
Quris Technologies is a bio-AI clinical-prediction platform is being developed to assure the safety and efficacy of medications.The company provides a fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively while minimizing animal testing, allowing pharmacompanies to avoid the enormous risks and costs of failed clinical trials and end the reliance on ineffective animal testing.Quris Technologies was established in 2019 by Isaac Bentwich in Tel Aviv, Israel. | $9M / Seed / Dec 20, 2022 | |
Behavidence
|
Behavidence utilizes AI to detect and monitor mental health conditions by identifying subtle changes in phone usage patterns. Behavidence now offers AI models for monitoring Depression, Anxiety, Stress, ADHD and PPD. The product has been adopted by health organizations, health technology, commercial and government entities across the globe. Inaddition to screening and for remote monitoring, Behavidence products can be used to detect comorbidities and as a measurement based outcome to predict relapse and therapeutic efficacy of interventions. It offers absolute user privacy, zero respondent burden and real time feedback. | $4.3M / Seed / Mar 10, 2022 | |
|
Quris
|
Quris Technologies is a bio-AI clinical-prediction platform is being developed to assure the safety and efficacy of medications.The company provides a fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively while minimizing animal testing, allowing pharmacompanies to avoid the enormous risks and costs of failed clinical trials and end the reliance on ineffective animal testing.Quris Technologies was established in 2019 by Isaac Bentwich in Tel Aviv, Israel. | $19M / Seed / Jan 11, 2022 | |
| See all 23 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Welltech Ventures invest in?
Welltech Ventures invests primarily in Health Care, Artificial Intelligence and mHealth startups, most often at Seed and Series A stage. Most of the 23 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Welltech Ventures's check size?
Welltech Ventures typically joins rounds of $718k–$19M at Seed and $6M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Welltech Ventures participates in.
How do I contact Welltech Ventures?
Public channels for Welltech Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Welltech Ventures?
The team at Welltech Ventures includes Amir Alroy (Co-Founder, Partner) and Steven Berelowitz (ADV., Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
